Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Assembly Biosciences Inc (ASMB) Insider Trading Activity
Healthcare • Biotechnology • 65 employees
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Total Value
$20,696,859.76
Total Shares
982,339
Average Trade Value
$1,724,738.31
Most Active Insider
Gilead Sciences, Inc.
Total Activity: $20,098,464
Largest Single Transaction
$20,098,464
by Gilead Sciences, Inc. on Dec 19, 2024
30-Day Activity
1 Transaction
Volume: 940,499 shares
Value: $20,098,464
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
10% Owner
|
Dec 19, 2024 | 940,499 | $20,098,464 | 2,209,471 (+42.6%) | Purchase | |
|
10% Owner
|
Nov 25, 2024 | 5,000 | $74,250 | 728,113 (+0.7%) | Purchase | |
|
10% Owner
|
Nov 25, 2024 | 2,976 | $44,640 | 723,113 (+0.4%) | Purchase | |
|
10% Owner
|
Nov 22, 2024 | 17,024 | $253,104 | 720,137 (+2.4%) | Purchase | |
|
Chief Manufacturing Officer
|
Nov 18, 2024 | 40 | $652 | 11,871 (-0.3%) | Sale | |
|
10% Owner
|
Oct 8, 2024 | 10,000 | $145,800 | 703,113 (+1.4%) | Purchase | |
|
Chief Manufacturing Officer
|
Oct 3, 2024 | 157 | $2,325 | 11,911 (-1.3%) | Sale | |
|
CEO and President
|
Oct 3, 2024 | 197 | $2,918 | 14,904 (-1.3%) | Sale | |
|
CEO and President
|
Aug 2, 2024 | 981 | $13,962 | 15,101 (-6.5%) | Sale | |
|
Chief Manufacturing Officer
|
Aug 2, 2024 | 785 | $11,173 | 12,068 (-6.5%) | Sale | |
|
10% Owner
|
Jul 5, 2024 | 4,438 | $55,564 | 693,113 (+0.6%) | Purchase | |
|
10% Owner
|
Jul 3, 2024 | 4,562 | $56,067 | 688,675 (+0.7%) | Purchase |